Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4404Urinary Bladder Neoplasms 1080Carcinoma, Renal Cell 1042Kidney Neoplasms 568Breast Neoplasms 454Neoplasms 406Carcinoma, Transitional Cell 301Neoplasm Metastasis 251Lung Neoplasms 243Testicular Neoplasms 202Melanoma 196Colorectal Neoplasms 194Ovarian Neoplasms 165Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 136Sarcoma 135Pancreatic Neoplasms 125Colonic Neoplasms 121Head and Neck Neoplasms 117Uterine Cervical Neoplasms 116Wilms Tumor 108Recurrence 106Motor Activity 100Urologic Neoplasms 90Stomach Neoplasms 89Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 81Adenocarcinoma 79

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Kidney Cancer × Genitourinary × Clear all
NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

British Columbia Cancer Agency

Phase 3 Not yet recruiting
142 enrolled
Genitourinary

Advanced Kidney Cancer

NCT05485883 2022-08-08

TILUR

Tianjin Medical University Second Hospital

Phase 2 Unknown
20 enrolled
Genitourinary

Advanced Kidney Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡